Structure via PubChem · Public domain (PubChem)
infigratinib
Sign in to saveAlso known as BGJ398, NVP-BGJ398
Infigratinib is an kinase inhibitor in development for the treatment of achondroplasia and hypochondroplasia.
Chemical data
- Formula
- C26H31Cl2N7O3
- Molecular weight
- 560.5 g/mol
- IUPAC name
- 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2021
- Admin. routes
- oral
- Indications
- glioblastoma multiforme, neoplasm, melanoma, cervical carcinoma
via ChEMBL · EBI
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Infigratinib is an kinase inhibitor in development for the treatment of achondroplasia and hypochondroplasia.
Infigratinib targets the fibroblast growth factor receptors FGFR1, FGFR2, and FGFR3.
Excerpted from Wikipedia’s “infigratinib” article, available under the CC BY-SA 4.0 licence.